Summary
44.96 0.22(0.48%)05/10/2024
Bristol-Myers Squibb Co. (BMY)
Bristol-Myers Squibb Co. (BMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.28 | 0.18 | -13.86 | -9.50 | -15.82 | -34.43 | 7.71 | 13,633.50 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 44.02 | |
| Open | 43.98 | |
| High | 44.26 | |
| Low | 43.84 | |
| Volume | 8,770,523 | |
| Change | 0.13 | |
| Change % | 0.28 | |
| Avg Volume (20 Days) | 14,243,158 | |
| Volume/Avg Volume (20 Days) Ratio | 0.62 | |
| 52 Week Range | 43.33 - 69.10 | |
| Price vs 52 Week High | -36.30% | |
| Price vs 52 Week Low | 1.59% | |
| Range | 0.09 | |
| Gap Up/Down | -0.64 | |
Fundamentals | ||
| Market Capitalization (Mln) | 91,098 | |
| EBIDTA | 18,172,000,256 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.2361 | |
| WallStreet Target Price | 52.25 | |
| Book Value | 8.1350 | |
| Earnings Per Share | -3.1000 | |
| EPS Estimate Current Quarter | -4.4400 | |
| EPS Estimate Next Quarter | 1.7500 | |
| EPS Estimate Current Year | 0.5600 | |
| EPS Estimate Next Year | 6.9200 | |
| Diluted EPS (TTM) | -3.1000 | |
| Revenues | ||
| Profit Marging | -0.1350 | |
| Operating Marging (TTM) | 0.1925 | |
| Return on asset (TTM) | 0.0539 | |
| Return on equity (TTM) | -0.2533 | |
| Revenue TTM | 45,533,999,104 | |
| Revenue per share TTM | 22.2120 | |
| Quarterly Revenue Growth (YOY) | 0.0470 | |
| Quarterly Earnings Growth (YOY) | -0.0890 | |
| Gross Profit (TTM) | 36,378,000,000 | |
| Dividends | ||
| Dividend Share | 2.3400 | |
| Dividend Yield | 0.0536 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 6.9300 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3249 | |
| Revenue Enterprise Value | 2.8226 | |
| EBITDA Enterprise Value | 6.5597 | |
| Shares | ||
| Shares Outstanding | 2,027,100,032 | |
| Shares Float | 2,022,964,812 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.10 | |
| Institutions (%) | 81.47 | |
05/11 07:29 EST - The Motley Fool
Is Bristol Myers' Dividend in Danger?
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow.
Is Bristol Myers' Dividend in Danger?
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow.
05/10 11:45 EST - MarketBeat
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
Savvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over the last 14 days and assigns a value from 0 to 100.
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
Savvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over the last 14 days and assigns a value from 0 to 100.
05/10 09:45 EST - The Motley Fool
2 Beaten-Down Stocks to Buy and Hold for 10 Years
Bristol Myers and Pfizer have experienced declining sales lately. However, both companies are rejuvenating their lineups.
2 Beaten-Down Stocks to Buy and Hold for 10 Years
Bristol Myers and Pfizer have experienced declining sales lately. However, both companies are rejuvenating their lineups.
05/06 14:22 EST - InvestorPlace
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in dividend stocks is one of the surest paths to building long-term wealth. Those who reinvest dividends compound their returns, building sustainable wealth in the long run.
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in dividend stocks is one of the surest paths to building long-term wealth. Those who reinvest dividends compound their returns, building sustainable wealth in the long run.
05/03 09:30 EST - The Motley Fool
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Bristol Myers stock is trading at multi-year lows and offers a sizable dividend yield. The drugmaker's scary-looking net loss is largely attributable to one-time outlays.
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Bristol Myers stock is trading at multi-year lows and offers a sizable dividend yield. The drugmaker's scary-looking net loss is largely attributable to one-time outlays.
05/03 07:15 EST - The Motley Fool
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
Bristol Myers Squibb has underperformed the S&P 500 over the past five years. The company's falling stock has driven up its dividend yield -- to a fat 4.9%.
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
Bristol Myers Squibb has underperformed the S&P 500 over the past five years. The company's falling stock has driven up its dividend yield -- to a fat 4.9%.
05/02 21:01 EST - Seeking Alpha
Bristol-Myers Squibb: A Lost Decade?
Bristol-Myers Squibb's share price reached new all-time highs in 2022, driven by a strong pipeline and new approvals. However, doubts arose about the company's ability to close the patent gap and achieve growth, leading to a sell-off. The company made several acquisitions, increasing its debt levels, but the long-term outlook remains uncertain.
Bristol-Myers Squibb: A Lost Decade?
Bristol-Myers Squibb's share price reached new all-time highs in 2022, driven by a strong pipeline and new approvals. However, doubts arose about the company's ability to close the patent gap and achieve growth, leading to a sell-off. The company made several acquisitions, increasing its debt levels, but the long-term outlook remains uncertain.
04/30 10:00 EST - Zacks Investment Research
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
04/29 18:22 EST - CNBC
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.
04/29 17:57 EST - Reuters
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.
04/27 08:15 EST - Seeking Alpha
2 Very Cheap Turnarounds Yielding Up To 7%
AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol-Myers Squibb has a strong pipeline and is undervalued. Both stocks offer potential for high income and capital appreciation if their valuations reset.
2 Very Cheap Turnarounds Yielding Up To 7%
AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol-Myers Squibb has a strong pipeline and is undervalued. Both stocks offer potential for high income and capital appreciation if their valuations reset.
04/25 13:00 EST - Zacks Investment Research
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
04/25 12:50 EST - Zacks Investment Research
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance.
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance.
04/25 11:57 EST - The Motley Fool
Why Bristol Myers Squibb Stock Is Sinking Today
Bristol Myers Squibb beat Wall Street estimates in the first quarter. However, the company slashed its full-year earnings outlook because of recent acquisitions and collaborations.
Why Bristol Myers Squibb Stock Is Sinking Today
Bristol Myers Squibb beat Wall Street estimates in the first quarter. However, the company slashed its full-year earnings outlook because of recent acquisitions and collaborations.
04/25 11:50 EST - InvestorPlace
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Bristol-Myers Squibb (NYSE: BMY ) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce. Bristol-Myers Squibb has revealed that it will reduce its headcount by 6%, or roughly 2,200 employees, with these layoffs.
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Bristol-Myers Squibb (NYSE: BMY ) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce. Bristol-Myers Squibb has revealed that it will reduce its headcount by 6%, or roughly 2,200 employees, with these layoffs.
04/25 10:37 EST - Zacks Investment Research
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
04/25 09:51 EST - Proactive Investors
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first quarter reached US$15.78 billion, topping analysts' expectations of US$15.2 billion.
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first quarter reached US$15.78 billion, topping analysts' expectations of US$15.2 billion.
04/25 08:36 EST - Barrons
Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts
The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.
Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts
The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.
04/25 07:35 EST - CNBC
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
04/25 07:03 EST - Market Watch
Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates
Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.911 billion, or $5.89 per share, after net income of $2.262 billion, or $1.07 per share, in the year earlier period.
Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates
Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.911 billion, or $5.89 per share, after net income of $2.262 billion, or $1.07 per share, in the year earlier period.